Moderna’s MRNA stock jumped in the US after the pharma company reported results that beat Wall Street expectations. The company posted a loss of $2.52 per share, improving from the prior year and well above the analyst estimate of a $3.96 loss. The surprise miss-to-beat shift sparked buying momentum.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
